Hybrid peptides constructed from RES-701-1, an endothelin B receptor antagonist, and endothelin; binding selectivity for endothelin receptors and their pharmacological activity
- 1 December 1998
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 6 (12) , 2459-2467
- https://doi.org/10.1016/s0968-0896(98)80020-5
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical development of endothelin receptor antagonistsTrends in Pharmacological Sciences, 1997
- RES‐701‐1: A Novel Endothelin ETB Receptor AntagonistCardiovascular Drug Reviews, 1996
- The current endothelin receptor classification: time for reconsideration?Trends in Pharmacological Sciences, 1994
- RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. II. Determination of the primary sequence.The Journal of Antibiotics, 1994
- RES-701-1,a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. I. Characterization of producing strain, fermentation, isolation, physico-chemical and biological properties.The Journal of Antibiotics, 1994
- Endothelin: progress in pharmacology and physiologyTrends in Pharmacological Sciences, 1993
- Endothelins—from receptors to medicineTrends in Pharmacological Sciences, 1993
- Endothelins 1The FASEB Journal, 1991
- Endothelins: a family of regulatory peptides. State-of-the-art lecture.Hypertension, 1991
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988